Terms: = Head and neck cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS
42 results:
1. Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.
Caeiro LD; Nakata Y; Borges RL; Zha M; Garcia-Martinez L; Bañuelos CP; Stransky S; Liu T; Chan HL; Brabson J; Domínguez D; Zhang Y; Lewis PW; Aznar Benitah S; Cimmino L; Bilbao D; Sidoli S; Wang Z; Verdun RE; Morey L
Genes Dev; 2024 Feb; 38(1-2):46-69. PubMed ID: 38286657
[TBL] [Abstract] [Full Text] [Related]
2. Hyperspectral imaging for monitoring of free flaps of the oral cavity: A feasibility study.
Felicio-Briegel A; Linek M; Sroka R; Rühm A; Freymüller C; Stocker M; Baumeister P; Reichel C; Volgger V
Lasers Surg Med; 2024 Feb; 56(2):165-174. PubMed ID: 38247042
[TBL] [Abstract] [Full Text] [Related]
3. Immunohistochemistry and oxygen saturation endoscopic imaging reveal hypoxia in submucosal invasive esophageal squamous cell carcinoma.
Minakata N; Sakashita S; Wakabayashi M; Nakamura Y; Sunakawa H; Yoda Y; Ishii G; Yano T
Cancer Med; 2023 Aug; 12(15):15809-15819. PubMed ID: 37329213
[TBL] [Abstract] [Full Text] [Related]
4. Targeting KDM2A Enhances T-cell Infiltration in nsd1-Deficient head and neck Squamous Cell Carcinoma.
Chen C; Shin JH; Fang Z; Brennan K; Horowitz NB; Pfaff KL; Welsh EL; Rodig SJ; Gevaert O; Gozani O; Uppaluri R; Sunwoo JB
Cancer Res; 2023 Aug; 83(16):2645-2655. PubMed ID: 37311054
[TBL] [Abstract] [Full Text] [Related]
5. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract] [Full Text] [Related]
6. nsd1 promotes esophageal cancer tumorigenesis via HIF1α signaling.
He F; Xiao H; Cai Y; Zhang N
Cell Biol Toxicol; 2023 Aug; 39(4):1835-1850. PubMed ID: 36522543
[TBL] [Abstract] [Full Text] [Related]
7. Understanding the Roles of the NSD Protein Methyltransferases in head and neck Squamous Cell Carcinoma.
Murali M; Saloura V
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360250
[TBL] [Abstract] [Full Text] [Related]
8. Detecting head and neck lymph node metastases with white light reflectance spectroscopy; a pilot study.
Bugter O; Aaboubout Y; Algoe M; de Bruijn HS; Keereweer S; Sewnaik A; Monserez DA; Koljenović S; Hardillo JAU; Robinson DJ; Baatenburg de Jong RJ
Oral Oncol; 2021 Dec; 123():105627. PubMed ID: 34826688
[TBL] [Abstract] [Full Text] [Related]
9. Identification of key factors shaping integrated levels of ACE2 and TMPRSS2 expression in head and neck squamous cell carcinoma.
Zheng T; Yue P; Han T; Zhang K; Jiang Y; Wang S; Jiang L; Zhao B; Zhang X; Yan X
Front Biosci (Landmark Ed); 2021 Oct; 26(10):740-751. PubMed ID: 34719202
[No Abstract] [Full Text] [Related]
10. Hyperactivation of MEK/ERK pathway by Ca
Najar MA; Aravind A; Dagamajalu S; Sidransky D; Ashktorab H; Smoot DT; Gowda H; Prasad TSK; Modi PK; Chatterjee A
Mol Carcinog; 2021 Nov; 60(11):769-783. PubMed ID: 34437731
[TBL] [Abstract] [Full Text] [Related]
11. Subtyping of head and neck squamous cell cancers based on immune signatures.
Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
[TBL] [Abstract] [Full Text] [Related]
12. Establishment of a Plasticity-Associated Risk Model Based on a SOX2- and SOX9-Related Gene Set in head and neck Squamous Cell Carcinoma.
Khorani K; Schwaerzler J; Burkart S; Kurth I; Holzinger D; Flechtenmacher C; Plinkert PK; Zaoui K; Hess J
Mol Cancer Res; 2021 Oct; 19(10):1676-1687. PubMed ID: 34285085
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Profiling Associated with Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2)-Mediated Carcinogenesis in Gastric cancer.
Najar MA; Modi PK; Ramesh P; Sidransky D; Gowda H; Prasad TSK; Chatterjee A
J Proteome Res; 2021 May; 20(5):2687-2703. PubMed ID: 33844560
[TBL] [Abstract] [Full Text] [Related]
14. All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
Kim HAJ; Zeng PYF; Shaikh MH; Mundi N; Ghasemi F; Di Gravio E; Khan H; MacNeil D; Khan MI; Patel K; Mendez A; Yoo J; Fung K; Lang P; Palma DA; Mymryk JS; Barrett JW; Boutros PC; Nichols AC
Oral Oncol; 2021 May; 116():105260. PubMed ID: 33725617
[TBL] [Abstract] [Full Text] [Related]
15. Chromatin dysregulation associated with nsd1 mutation in head and neck squamous cell carcinoma.
Farhangdoost N; Horth C; Hu B; Bareke E; Chen X; Li Y; Coradin M; Garcia BA; Lu C; Majewski J
Cell Rep; 2021 Feb; 34(8):108769. PubMed ID: 33626351
[TBL] [Abstract] [Full Text] [Related]
16. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
Rajagopalan KN; Chen X; Weinberg DN; Chen H; Majewski J; Allis CD; Lu C
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619101
[TBL] [Abstract] [Full Text] [Related]
17. Remote monitoring of head and neck free flaps using near infrared spectroscopic tissue oximetry.
Starr NC; Slade E; Gal TJ; Adekunle A; Bigler D; Cheung B; Wang D; Yeoh M; Liau J; Kejner A
Am J Otolaryngol; 2021; 42(1):102834. PubMed ID: 33229129
[TBL] [Abstract] [Full Text] [Related]
18. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.
Liang S; Li C; Gao Z; Li J; Zhao H; Yu J; Meng X
Int Immunopharmacol; 2021 Jan; 90():107178. PubMed ID: 33218939
[TBL] [Abstract] [Full Text] [Related]
19. Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of head and neck Squamous Cell Carcinoma.
Holt J; Walter V; Yin X; Marron D; Wilkerson MD; Choi HY; Zhao X; Jo H; Hayes DN; Ko YH
Clin Cancer Res; 2021 Feb; 27(3):831-842. PubMed ID: 33148669
[TBL] [Abstract] [Full Text] [Related]
20. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO sto 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract] [Full Text] [Related]
[Next]
